[{"orgOrder":0,"company":"Topokine Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"XAF5","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Topokine Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Topokine Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Topokine Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Topokine Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"XAF5","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Topokine Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Topokine Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Topokine Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"scPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Universidad de Granada","sponsor":"Puleva Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Universidad de Granada","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de Granada \/ Puleva Biotech","highestDevelopmentStatusID":"9","companyTruncated":"Universidad de Granada \/ Puleva Biotech"},{"orgOrder":0,"company":"Af?liated Hospital of North Sichuan Medical College","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Af?liated Hospital of North Sichuan Medical College","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Af?liated Hospital of North Sichuan Medical College \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Af?liated Hospital of North Sichuan Medical College \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Sichuan Provincial People's Hospital","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Sichuan Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Provincial People's Hospital \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Sichuan Provincial People's Hospital \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Albert Einstein Healthcare Network \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Arvinas","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Arvinas"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"AstraZeneca | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ AstraZeneca | Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ AstraZeneca | Eli Lilly"},{"orgOrder":0,"company":"Isfahan University of Medical Sciences","sponsor":"Adibvira","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRAN","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Isfahan University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isfahan University of Medical Sciences \/ Adibvira","highestDevelopmentStatusID":"9","companyTruncated":"Isfahan University of Medical Sciences \/ Adibvira"},{"orgOrder":0,"company":"Bergman Clinics","sponsor":"Zimmer Biomet","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bergman Clinics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bergman Clinics \/ Zimmer Biomet","highestDevelopmentStatusID":"9","companyTruncated":"Bergman Clinics \/ Zimmer Biomet"},{"orgOrder":0,"company":"National Liver Institute, Egypt","sponsor":"Pharco Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"National Liver Institute, Egypt","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Liver Institute, Egypt \/ Pharco Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"National Liver Institute, Egypt \/ Pharco Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Grazoprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Grazoprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IAH0968","moa":"HER2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IAH0968","moa":"HER2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SunHo BioPharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SunHo BioPharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Iron Isomaltoside","moa":"Iron","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oslo University Hospital \/ Pharmacosmos AS","highestDevelopmentStatusID":"9","companyTruncated":"Oslo University Hospital \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Praxair Distribution","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gas for Inhalation","sponsorNew":"Boston Children's Hospital \/ Praxair Distribution","highestDevelopmentStatusID":"9","companyTruncated":"Boston Children's Hospital \/ Praxair Distribution"},{"orgOrder":0,"company":"Total Definer Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Total Definer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Total Definer Research Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Total Definer Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Obstetrix Medical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Obstetrix Medical Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Obstetrix Medical Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Obstetrix Medical Group \/ Undisclosed"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gynuity Health Projects \/ Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C","highestDevelopmentStatusID":"9","companyTruncated":"Gynuity Health Projects \/ Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C"},{"orgOrder":0,"company":"American University of Beirut Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"LEBANON","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"American University of Beirut Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American University of Beirut Medical Center \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"American University of Beirut Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC189","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Yasoo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Aquavanta","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Yasoo Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yasoo Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yasoo Health \/ Undisclosed"},{"orgOrder":0,"company":"Fonterra Research Centre","sponsor":"Danisco | Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NEW ZEALAND","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Bifidobacterium Lactis HN019","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Fonterra Research Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fonterra Research Centre \/ Danisco | Sprim Advanced Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Fonterra Research Centre \/ Danisco | Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Taejoon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CTO0303-A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Taejoon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taejoon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Taejoon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Dpt-Hb-Hib Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno","sponsor":"Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ARGENTINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Gamma Variant Rbd-Based Arvac-Cg Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno \/ Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory","highestDevelopmentStatusID":"9","companyTruncated":"Centro de Educaci\u00f3n Medica e Investigaciones Cl\u00ednicas Norberto Quirno \/ Universidad Nacional de San Mart\u00edn | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HRIG","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Human Platelets","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"9","companyTruncated":"Cellphire Therapeutics \/ U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"I004","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"Incepta Vaccine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BANGLADESH","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Ingovax ACWY","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Incepta Vaccine","highestDevelopmentStatusID":"9","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Incepta Vaccine"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pharmbio Korea","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seoul National University Hospital \/ Pharmbio Korea","highestDevelopmentStatusID":"9","companyTruncated":"Seoul National University Hospital \/ Pharmbio Korea"},{"orgOrder":0,"company":"Curadel Surgical Innovations, Inc.","sponsor":"Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nizaracianine Triflutate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Curadel Surgical Innovations, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curadel Surgical Innovations, Inc. \/ Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai","highestDevelopmentStatusID":"9","companyTruncated":"Curadel Surgical Innovations, Inc. \/ Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai"},{"orgOrder":0,"company":"NTC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NTC015","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"NTC \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NTC \/ Undisclosed"},{"orgOrder":0,"company":"Mucosa innovations","sponsor":"Universidad de Granada","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Mucosa innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mucosa innovations \/ Universidad de Granada","highestDevelopmentStatusID":"9","companyTruncated":"Mucosa innovations \/ Universidad de Granada"},{"orgOrder":0,"company":"Murdoch Childrens Research Institute","sponsor":"Institut Pasteur | Menzies School of Health Research | National Health and Medical Research Council, Australia | Bill & Melinda Gates Foundation | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PCV10","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Murdoch Childrens Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Murdoch Childrens Research Institute \/ Institut Pasteur | Menzies School of Health Research | National Health and Medical Research Council, Australia | Bill & Melinda Gates Foundation | GSK","highestDevelopmentStatusID":"9","companyTruncated":"Murdoch Childrens Research Institute \/ Institut Pasteur | Menzies School of Health Research | National Health and Medical Research Council, Australia | Bill & Melinda Gates Foundation | GSK"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Aix Scientifics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Rescap","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Alloksys Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloksys Life Sciences \/ Aix Scientifics","highestDevelopmentStatusID":"9","companyTruncated":"Alloksys Life Sciences \/ Aix Scientifics"},{"orgOrder":0,"company":"Vinbiocare Biotechnology Joint Stock Company","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"VIETNAM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RNA SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Vinbiocare Biotechnology Joint Stock Company","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vinbiocare Biotechnology Joint Stock Company \/ Arcturus Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Vinbiocare Biotechnology Joint Stock Company \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Seasonal Trivalent Split, Inactivated Influenza Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SWIM816","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemirna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Stemirna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins Bloomberg School of Public Health","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh | United Nations World Food Programme (WFP) | DSM Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Wheat Soy Blend","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Johns Hopkins Bloomberg School of Public Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins Bloomberg School of Public Health \/ International Centre for Diarrhoeal Disease Research, Bangladesh | United Nations World Food Programme (WFP) | DSM Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Johns Hopkins Bloomberg School of Public Health \/ International Centre for Diarrhoeal Disease Research, Bangladesh | United Nations World Food Programme (WFP) | DSM Ltd"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Varicella Vaccine","moa":"Varicella-zoster virus gH\/gL","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fampridine","moa":"Voltage-gated potassium channel","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"London Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"London Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Drops","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"SINTETICA SA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SINTETICA SA \/ Undisclosed"},{"orgOrder":0,"company":"L'Oreal","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"L'Oreal","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Serum","sponsorNew":"L'Oreal \/ Goldman, Butterwick, Fitzpatrick and Groff","highestDevelopmentStatusID":"9","companyTruncated":"L'Oreal \/ Goldman, Butterwick, Fitzpatrick and Groff"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Christopher Bell","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Christopher Bell","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Christopher Bell"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : CTO0303-A is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 24, 2024

                          Lead Product(s) : CTO0303-A

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          L'Oreal

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          L'Oreal

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Vitamin C is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Ascorbic Acid

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Goldman, Butterwick, Fitzpatrick and Groff

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Gynuity Health Projects

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Gynuity Health Projects

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Lead Product(s) : Levonorgestrel

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase II/ Phase III

                          Sponsor : Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Levonorgestrel is a Hormone drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy, Early.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          July 09, 2024

                          Lead Product(s) : Levonorgestrel

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Cuidado Integral de la Mujer, Gineclinic, S.C. | Servicios de Salud Medieg, A. C

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Jiaxing AnDiCon Biotech

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Jiaxing AnDiCon Biotech

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : ADC189 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 02, 2024

                          Lead Product(s) : ADC189

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Curadel Surgical Innovations, Inc.

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Curadel Surgical Innovations, Inc.

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Lead Product(s) : Nizaracianine Triflutate

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase II/ Phase III

                          Sponsor : Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nizaracianine Triflutate is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 26, 2023

                          Lead Product(s) : Nizaracianine Triflutate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Leiden University Medical Center | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | University of Massachusetts Chan Medical School, Worcester | Stanford University | Cedars-Sinai

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : SWIM816 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 20, 2023

                          Lead Product(s) : SWIM816

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Lead Product(s) : Gamma Variant Rbd-Based Arvac-Cg Vaccine

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase II/ Phase III

                          Sponsor : Universidad Nacional de San Martín | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Gamma Variant Rbd-Based Arvac-Cg Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          March 02, 2023

                          Lead Product(s) : Gamma Variant Rbd-Based Arvac-Cg Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Universidad Nacional de San Martín | National Council of Scientific Research, Argentina | Pablo Cassara Laboratory

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : IAH0968 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 06, 2023

                          Lead Product(s) : IAH0968

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : I004 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 14, 2022

                          Lead Product(s) : I004

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : PIKA COVID-19 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 19, 2022

                          Lead Product(s) : PIKA COVID-19 Vaccine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank